Benefits of PARP Inhibitor Use in Breast Cancer

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.

ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.

For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.

Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.